Cardiovascular Systems ROA 2006-2018 | CSII

Current and historical return on assets (ROA) values for Cardiovascular Systems (CSII) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Cardiovascular Systems ROA for the three months ending June 30, 2018 was 0.88%.
Cardiovascular Systems Annual ROA
2018 0.84
2017 -0.92
2016 -39.34
2015 -19.16
2014 -19.40
2013 -24.81
2012 -26.60
2011 -23.79
2010 -55.95
2009 -44.07
2008 -87.80
2008 -93.35
2007 8.12
2007 0.00
2006 -21.58
2006 -386.38
2005 -52.96
2005 0.00
Cardiovascular Systems Quarterly ROA
Q4 2018 1.84
Q3 2018 0.19
Q2 2017 -0.22
Q1 2017 -1.04
Q4 2017 0.40
Q3 2017 -0.94
Q2 2016 0.66
Q1 2016 -1.34
Q4 2016 -3.43
Q3 2016 -15.67
Q2 2015 -10.03
Q1 2015 -8.17
Q4 2015 -5.06
Q3 2015 -5.97
Q2 2014 -2.92
Q1 2014 -4.51
Q4 2014 -5.29
Q3 2014 -5.24
Q2 2013 -4.78
Q1 2013 -7.67
Q4 2013 -7.06
Q3 2013 -6.28
Q2 2012 -10.18
Q1 2012 -8.67
Q4 2012 -7.30
Q3 2012 -8.41
Q2 2011 -7.95
Q1 2011 -7.99
Q4 2011 -5.31
Q3 2011 -5.45
Q2 2010 -4.45
Q1 2010 -10.06
Q4 2010 -10.30
Q3 2010 -10.52
Q2 2009 -10.63
Q1 2009 -8.80
Q4 2009 -3.65
Q3 2009 -5.05
Q2 2008 0.00
Q1 2008 -26.29
Q4 2008 0.00
Q3 2008 -13.03
Q2 2007 0.00
Q1 2007 -11.51
Q4 2007 0.00
Q3 2007 -6.80
Q2 2006 0.00
Q1 2006 -4.01
Q4 2006 -5.85
Q3 2006 0.00
Q2 2005 -20.57
Q1 2005 0.00
Q4 2005 0.00
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $1.264B $0.217B
Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360? Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease; and a range of plaque types, including calcified vessel lesions. The Diamondback 360? removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company refined its `orbital` technology to address the growing market need of providing a safer more effective atherectomy device.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $130.270B 19.97
Abbott Laboratories (ABT) United States $120.171B 25.18
Stryker (SYK) United States $64.899B 25.08
Boston Scientific (BSX) United States $51.846B 26.97
Baxter (BAX) United States $41.480B 28.23
Zimmer Biomet Holdings (ZBH) United States $26.421B 16.97
Smith & Nephew SNATS (SNN) United Kingdom $16.200B 0.00
ResMed (RMD) United States $16.068B 31.90
Canopy Growth (CGC) Canada $11.278B 0.00
Perrigo (PRGO) Ireland $10.034B 14.24
Bio-Rad Laboratories (BIO) United States $8.905B 57.18
Hill-Rom Holdings (HRC) United States $6.097B 20.68
Insulet (PODD) United States $6.090B 0.00
Haemonetics (HAE) United States $5.674B 51.78
ICU Medical (ICUI) United States $5.462B 37.01
Neogen (NEOG) United States $4.728B 75.23
GW Pharmaceuticals (GWPH) United Kingdom $4.267B 0.00
Agios Pharmaceuticals (AGIO) United States $4.204B 0.00
Hutchison China MediTech (HCM) China $3.776B 0.00
NuVasive (NUVA) United States $3.601B 34.16
National Vision Holdings (EYE) United States $3.257B 71.93
Quidel (QDEL) United States $2.673B 54.77
NxStage Medical (NXTM) United States $1.849B 0.00
Phibro Animal Health (PAHC) United States $1.722B 24.51
AtriCure (ATRC) United States $1.253B 0.00
VAREX IMAGING (VREX) United States $1.144B 18.69
Omeros (OMER) United States $1.141B 0.00
Owens & Minor (OMI) United States $1.069B 11.43
PetIQ (PETQ) United States $1.026B 33.57
Eagle Pharmaceuticals (EGRX) United States $1.019B 30.08
Surmodics (SRDX) United States $1.000B 120.81
Cerus (CERS) United States $0.978B 0.00
MacroGenics (MGNX) United States $0.966B 0.00
OraSure Technologies (OSUR) United States $0.949B 62.08
TG Therapeutics (TGTX) United States $0.741B 0.00
LeMaitre Vascular (LMAT) United States $0.678B 32.50
Insys Therapeutics (INSY) United States $0.676B 0.00
Meridian Bioscience (VIVO) United States $0.634B 21.67
Lantheus Holdings (LNTH) United States $0.617B 19.17
NanoString Technologies (NSTG) United States $0.506B 0.00
Evolus (EOLS) United States $0.504B 0.00
Quanterix (QTRX) United States $0.412B 0.00
Cytosorbents (CTSO) United States $0.407B 0.00
Utah Medical Products (UTMD) United States $0.353B 22.73
Surface Oncology (SURF) United States $0.320B 0.00
BioLife Solutions (BLFS) United States $0.286B 0.00
Bovie Medical (BVX) United States $0.241B 0.00
Rockwell Medical (RMTI) United States $0.217B 0.00
Chimerix (CMRX) United States $0.183B 0.00
Fonar (FONR) United States $0.156B 7.76
Conatus Pharmaceuticals (CNAT) United States $0.142B 0.00
Chembio Diagnostics (CEMI) United States $0.136B 0.00
Female Health (VERU) United States $0.100B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.082B 0.00
Trinity Biotech (TRIB) Ireland $0.081B 24.13
United-Guardian (UG) United States $0.077B 16.87
Neurotrope (NTRP) United States $0.068B 0.00
InfuSystems Holdings (INFU) United States $0.065B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.060B 0.00
CAS Medical Systems (CASM) United States $0.057B 0.00
ImmuCell (ICCC) United States $0.042B 0.00
Capricor Therapeutics (CAPR) United States $0.034B 0.00
Myomo (MYO) United States $0.027B 0.00
Valeritas Holdings (VLRX) United States $0.024B 0.00
Akers Biosciences Inc (AKER) United States $0.023B 0.00
Senestech (SNES) United States $0.016B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
NeuroMetrix (NURO) United States $0.010B 0.00
Cellectar Biosciences (CLRB) United States $0.009B 0.00